Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.

Goldberg SB, Ahn MJ, Baik C, De Castro Carpeño J, Cho BC, de Langen AJ, Fidler MJ, Goldman JW, Grønberg BH, Akamatsu H, Kim SW, Kim YJ, Le X, Marrone KA, Piotrowska Z, Riess JW, Shiraishi Y, Fraenkel PG, Merchan Ruiz B, Smith PE, Tang KH, Yu HA

Open source

DOI: 10.1158/1078-0432.ccr-26-0704
Published: 2026 Jul 13
Container: Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-26-0704,
  title = {Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.},
  author = {Goldberg SB and Ahn MJ and Baik C and De Castro Carpeño J and Cho BC and de Langen AJ and Fidler MJ and Goldman JW and Grønberg BH and Akamatsu H and Kim SW and Kim YJ and Le X and Marrone KA and Piotrowska Z and Riess JW and Shiraishi Y and Fraenkel PG and Merchan Ruiz B and Smith PE and Tang KH and Yu HA},
  year = {2026},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-26-0704},
  url = {https://doi.org/10.1158/1078-0432.ccr-26-0704}
}

RIS

TY  - JOUR
TI  - Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.
AU  - Goldberg SB
AU  - Ahn MJ
AU  - Baik C
AU  - De Castro Carpeño J
AU  - Cho BC
AU  - de Langen AJ
AU  - Fidler MJ
AU  - Goldman JW
AU  - Grønberg BH
AU  - Akamatsu H
AU  - Kim SW
AU  - Kim YJ
AU  - Le X
AU  - Marrone KA
AU  - Piotrowska Z
AU  - Riess JW
AU  - Shiraishi Y
AU  - Fraenkel PG
AU  - Merchan Ruiz B
AU  - Smith PE
AU  - Tang KH
AU  - Yu HA
PY  - 2026
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-26-0704
UR  - https://doi.org/10.1158/1078-0432.ccr-26-0704
ER  -

APA

SB, G., MJ, A., C, B., J, D. C. C., BC, C., AJ, D. L., MJ, F., JW, G., BH, G., H, A., SW, K., YJ, K., X, L., KA, M., Z, P., JW, R., Y, S., PG, F., B, M. R., PE, S., KH, T., & HA, Y. (2026). Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-26-0704

Source records

pubmed · retrieved 2026-09-26T11:30:22.520Z